Iterum Therapeutics Stock (NASDAQ:ITRM)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$1.08

52W Range

$0.81 - $3.02

50D Avg

$0.99

200D Avg

$1.34

Market Cap

$45.20M

Avg Vol (3M)

$579.79K

Beta

2.82

Div Yield

-

ITRM Company Profile


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance


ITRM Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.70M$-47.47M$-30.38M
Net Income$-24.77M$-38.37M$-44.43M
EBITDA$-18.70M$-34.58M$-39.97M
Basic EPS$-1.26$-2.96$-3.63
Diluted EPS$-1.26$-2.96$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 13, 25 | 8:30 AM
Q4 24Feb 07, 25 | 8:30 AM
Q3 24Nov 14, 24 | 8:30 AM

Peer Comparison


TickerCompany
VISLVislink Technologies, Inc.
OTLKOutlook Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
GRCEGrace Therapeutics, Inc.
TRAWTraws Pharma, Inc.